News >

Future Looks Bright for CAR T-Cell Therapies in Hematologic Malignancies

Brandon Scalea
Published: Wednesday, May 08, 2019

Nirav N. Shah, MD

Nirav N. Shah, MD

CD19-directed CAR T-cell therapy has demonstrated impressive responses in select patients with refractory hematologic malignancies, and ongoing research may further increase the durability of this clinical activity, said Nirav N. Shah, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication